Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study-Reference-Cited by-同舟云学术

Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study

Published:2020-05-28 Issue:3 Volume:38 Page:318-325
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Clausen Michael R.¹^ORCID,Ulrichsen Sinna P.²,Juul Maja B.³,Poulsen Christian B.⁴,Iversen Brian⁵,Pedersen Per T.⁶,Madsen Jakob⁷,Pedersen Robert S.⁸,Josefsson Pär L.⁹,Gørløv Jette S.¹⁰,Nørgaard Mette²,d'Amore Francesco¹

Affiliation:

1. Department of Hematology Aarhus University Hospital Aarhus Denmark

2. Department of Clinical Epidemiology Aarhus University Hospital Aarhus Denmark

3. Department of Hematology Odense University Hospital Odense Denmark

4. Department of Hematology Zealand University Hospital Roskilde Denmark

5. Department of Hematology Sygehus Lillebaelt Vejle Denmark

6. Department of Hematology Sydvestjysk Sygehus Esbjerg Denmark

7. Department of Hematology Aalborg University Hospital Aalborg Denmark

8. Department of Medicine Hospitalsenheden Vest Holstebro Denmark

9. Department of Hematology Herlev University Hospital Herlev Denmark

10. Department of Hematology Rigshospitalet Copenhagen Denmark

Funder

Aase og Ejnar Danielsens Fond

Dagmar Marshalls Fond

Dansk Kræftforsknings Fond

Eva og Henry Frænkels Mindefond

Karen Elise Jensens Fond

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2734

Reference42 articles.

1. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the GermanHigh-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)

2. Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis

3. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma

4. Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma

5. Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin’s lymphoma